CTOs on the Move

Professional Gem Sciences Inc

www.progem.com

 
Professional Gem Sciences Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.progem.com
  • 5 S Wabash Ave Ste 1905
    Chicago, IL USA 60603
  • Phone: 312.920.1541

Executives

Name Title Contact Details

Similar Companies

Bioxene

Bioxene is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novo Nordisk

Headquartered in Denmark, Novo Nordisk has more than 5,000 employees in the United States – representing 16% of the total workforce. From our insulin product manufacturing facility in Clayton, , North Carolina, to our Research and Development Center in Seattle, Washington we bring value to communities across the country in a variety of ways.   Our newly constructed LEED-certified building in Plainsboro, New Jersey, is modeled on principles of functionality, innovation, openness, quality, and aesthetics-offering a space that promotes collaboration and creativity.

EAG Life Sciences

EAG Life Sciences is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamatrix

Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.